# Efficacy of Infliximab in the Treatment of Patients Affected by Corticodependent Crohn's Disease (P02732)

> **NCT00796250** · PHASE3 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 9 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **BIOLOGICAL:** Infliximab
- **DRUG:** AZA
- **DRUG:** Placebo Prednisolone
- **DRUG:** Prednisolone
- **DRUG:** AZA
- **BIOLOGICAL:** Placebo Infliximab

## Key facts

- **NCT ID:** NCT00796250
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-11-01
- **Primary completion:** 2005-01-01
- **Final completion:** 2005-01-01
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Due to poor patient recruitment, a decision was made to terminate this trial.
- **Last updated:** 2017-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00796250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00796250, "Efficacy of Infliximab in the Treatment of Patients Affected by Corticodependent Crohn's Disease (P02732)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00796250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*